Can quick drug optimization after heart failure hospitalization save lives in women?

NCT ID NCT07295522

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether quickly starting and increasing guideline-recommended heart failure medications after hospitalization improves outcomes in women. About 360 women from 13 Italian hospitals will be randomly assigned to either a high-intensity care group (rapid drug optimization) or usual care. Researchers will track deaths, hospital readmissions, and worsening heart failure over one year to see if the intensive approach is safer and more effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Guideline-directed medical therapy (GDMT) including beta-blockers, ACE inhibitors, ARBs, ARNIs, mineralocorticoid receptor antagonists, and SGLT2 inhibitors

What this could lead to

If successful, this could show that a rapid, intensive medication strategy after heart failure hospitalization reduces deaths and readmissions, especially for women.

What could go wrong

This is a Phase 4 study with a moderate sample size, so results may not apply to all heart failure patients. The intensive drug regimen may cause side effects or be poorly tolerated in some women.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Azienda Ospedaliero Universitaria Delle Marche

    Ancona, Italy

  • Azienda Sanitaria Locale Bari

    Bari, Italy

  • Azienda USL IRCCS Di Reggio Emilia

    Reggio Emilia, Italy

  • Azienda USL Toscana Centro

    Florence, Italy

  • Azienda USL Toscana Nord Ovest - Cecina

    Cecina, Italy

  • Centro Cardiologico Monzino

    Milan, Italy

  • Fondazione Policlinico Universitario Campus Bio-medico

    Roma, Italy

  • Fondazione Toscana Gabriele Monasterio

    Pisa, Italy

  • IRCCS Policlinico San Donato

    San Donato Milanese, MILANO, 20097, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Istituto Auxologico Italiano

    Milan, Italy

  • Ospedale S. Maria delle Croci

    Ravenna, Italy

  • Ospedale San Camillo Forlanini

    Roma, Italy

  • Ospedale Universitario di Ferrara

    Ferrara, Italy